Slides
Page 1
6 August 2025 Q2/H1 2025 Earnings Report
Page 2
* CER (constant exchange rate) calculation is based on 2024 actual FX rate (HUFEUR = 395.5) ** Inventory and receivables impairment and write-off/back is part of Clean EBIT from Jan 2025 (recalculated 2024 Clean EBIT: HUF 265bn; EUR 671mn)2 H1 2025 highlights – tracking in line with guidance after strong Q2 HUF 457.6bn (EUR 1.13bn) +10.7% Pharma sales Clean EBIT2 HUF 148.2bn (EUR 366mn) +15.1% EBIT1 HUF 140.4bn (EUR 347mn) +11.0% Free Cash-flow3 HUF 110.8bn HUF -0.5bn EPS HUF 656 H1 Q1 Q1-Q3 FY Return on Equity4 17.0% -2.6ppt 1 EBIT: Profit/loss from operations 2 Clean EBIT (cEBIT)**: Gross profit less op. expenses (S&M, G&A, R&D) less clawback, less inventory and receivables impairment and write-off/back plus milestone income. cEBIT reflects the profitability of the core business, excl. one-offs 3 Free Cash Flow: Operating Cash flow after changes in Net Working Capital plus interest received less Capex (PP&E) 4 Return on Equity: Cumulative net profit for the last 4 quarters divided by the actual quarter's equity 1 Pharma Revenues (CER*) (EUR 2.3-2.4bn) around +10% Clean EBIT (CER*) around +10% 2025 guidance H1 2025 CER revenue (EUR 1.13bn) grew by 8% (FX added c. 3ppt to reported growth) H1 2025 CER Clean EBIT (EUR 357mn) rose by 10% -13.2%↓ ↓
Page 3
3 Financial and operational highlights • Pharma revenues grew by 11% YoY to HUF 237.5bn in Q2 2025, bringing H1 2025 revenues to HUF 458bn (+11% YoY) • CER (ex-FX) revenue growth was 8% in H1 2025, catching up with the annual guidance (around +10%); FX provided c. 3ppt tailwind to reported revenues in H1 • Vraylar sales and WHC revenues were the main drivers in Q2, both delivering double-digit growth (even on a CER basis) both in Q2 and H1; GenMed and BIO saw some slowing dynamics in Q2 • Gross profit (pharma) grew by 11% to HUF 321bn in H1 2025, while gross margin was marginally higher (+0.2ppt) at 70.2% • Clean EBIT (pharma) jumped by 21% to HUF 79bn in Q2 2025, bringing H1 Clean EBIT to HUF 147bn, up by 14.5%. CER (ex-FX) Clean EBIT increased by 10% YoY (EUR 357mn), in line with the annual guidance. • Free cash flow (before M&A) was nearly unchanged YoY at HUF 111bn in H1 2025, as higher EBIT and lower capex was offset by some realized FX losses. Cash was used only in smaller transactions, while the majority of the FCF was paid out in Q2 as the regular annual dividend (HUF 93bn, +18% YoY). • Richter strengthened collaboration with Granata Bio in Fertility, as part of its commitment to expand its WHC presence in the US market • Richter received European Commission approval for Junod® and Yaxwer®, its biosimilar denosumab products for bone disease and osteoporosis • AbbVie-partnered program, RGH-932 (D2/D3 agonist) entered into Phase 2 development in Generalized Anxiety Disorder, the second Phase 2 clinical trial related to the molecule Financial highlights Business drivers and key events (Q2 2025)
Page 4
ESG: Sustainable operations from production to administration 4 ➢ Crucial milestones were achieved towards meeting our strategic goal to cover c.50% of our Hungarian electricity consumption from renewable sources ➢ 60%+ YoY increase in our own renewable electricity generation in H1 2025, driven by new solar systems in Romania and Hungary ➢ 3-year green power purchase agreement (PPA) signed in July 2025, ensuring 24 GWh/year of wind and solar electricity from 2026 ➢ We also keep on purchasing some certified green electricity (GO certificates) ➢ The hybrid approach (own solar + purchased green energy) helps significantly reduce environmental impact and improve supply reliability Richter’s Paperless Transformation ➢ Approx. 60% reduction in company-wide paper use since the program’s launch in 2018 ➢ 19% decrease achieved in 2024 alone, continuing a strong downward trend ➢ Ongoing digitalisation efforts include electronic lab records, digital payroll and invoicing, and paperless documentation in manufacturing and R&D ➢ In 2025, we are further scaling up paper reduction by: ➢ expanding digital batch documentation in our tableting unit ➢ introducing paperless maintenance processes in our technical departments ➢ launching new electronic modules to support training and quality issue tracking Renewable energy procurement and production 2018 2020 2022 2024 109 885 70 396 60 984 45 680 -36% -13% -25% Paper use - Weight (kg)
Page 5
55 Financial Highlights
Page 6
All data in HUFbn Pharmaceutical revenues (ex-FX) rose by 7.6% in H1 2025 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 213.3 213.5 217.9 220.1 237.5 +11.4% Pharmaceutical Revenues (HUF bn) Pharmaceutical Revenues, cumulative (HUF bn, EUR mn) H1 2024 H1 2025 H1 2025 W/o Fx effect 413.4 457.6 444.8 +10.7% +7.6% Pharma other BIO WHC GM CNS Pharmaceutical Revenues by region (HUF bn) H1 2025 (EURmn) CER 1,132 Impact of the exchange rate changes on revenues (HUF bn) Western Europe Central Europe Eastern Europe North America Asia & Pacific Latin America Rest of the World 76.1 86.0 86.4 91.0 84.6 98.0 116.5 131.2 29.5 31.5 15.7 15.1 4.6 4.7 H1 2024 H1 2025 Q1 2025 0.5-0.2 Q2 2025 H1 2025 USDRUBEUROther 4.71.11.61.4 2.21.5 5.23.33.11.2 6
Page 7
All data in HUFbn Accelerating WHC, slowing GenMed dynamics in Q2 WHC Revenues GM Revenues BIO Revenues CNS ex-Vraylar® Revenues • WHC sales growth accelerated significantly in Q2 (+19%), bringing the H1 growth into the double- digit range, even if adjusted for FX and despite the significant base effect (pre-shipments in H1 2024). Bulk of the growth was delivered by Western and Eastern European markets. All focus therapeutic segments (fertility, menopause and endometriosis) saw double-digit growth in both Q2 and H1 and even contraception recorded higher sales YoY. • GenMed revenues growth saw a material slowdown in Q2, affected by the high base and weaker volumes, despite supportive FX and pricing. Consequently, the FX-adjusted growth was only 5% in H1 YoY. • BIO revenues growth moderated in Q2 on somewhat weaker CDMO dynamics, hence the H1 growth was at 9% (ex-FX) • CNS (ex-Vraylar®) revenues picked up somewhat in Q2 (+7%), but remained affected by timing of shipments of Reagila® at some of the partners, thus the sluggish H1 performance Key messages H1 2024 H1 2025 H1 2025 W/o Fx effect 149.5 168.8 164.7 +12.9% +10.2% H1 2024 H1 2025 H1 2025 W/o Fx effect 121.4 130.8 127.7 +7.7% +5.2% H1 2024 H1 2025 H1 2025 W/o Fx effect 26.5 29.4 28.9 +11.0% +8.9% H1 2024 H1 2025 H1 2025 W/o Fx effect 7.2 7.4 7.2 +3.6% +0.1% 7
Page 8
Operating expenses (pharma) (HUFbn) Operating costs as a % of Pharma revenues (%) All data in HUFbn Moderating opex growth (+9.5% in H1 YoY) 30 31 28 36 30 30 31 31 30 30 20 20 19 18 19 19 17 21 20 18 10 12 11 10 11 11 12 13 11 11 7 6 6 6 6 7 6 6 0 5 10 15 20 25 30 35 40 6 Q1 23 Q2 23 Q3 23 6 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Operating costs as a % of Pharma revenues (%) Cost of Sales S&M R&D G&A 33 32 31 31 30 21 21 19 19 19 12 11 10 12 11 5 5 6 7 6 0 5 10 15 20 25 30 35 FY 2021 FY 2022 FY 2023 FY 2024 H1 2025 Cost of Sales S&M R&D G&A Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 76.9 74.7 90.5 81.9 83.1 41.0 22.6 13.3 36.9 24.9 12.9 45.2 29.0 16.3 44.0 23.8 14.1 43.7 25.1 14.3 +8.0% Key messages • Cost of Sales remained broadly unchanged at c. 30% of sales, implying little change in gross margins (70.2% in H1 2025 vs. 70.0% a year ago) • Operating expenses were up by 8% in Q2 2025 YoY (and 9.5% in H1 YoY), showing a further deceleration, now below rate of sales growth • R&D expenses grew by 8% in H1 2025 (and stood at 11% of sales), as a decline in BIO R&D partly offset a material increase in WHC • Sales & Marketing expenses increased by 10% in H1 2025 YoY (only +7.5% ex- FX), driven primarily by the CEU, EEU and APAC regions (investments in salesforce, increased promotional activity) • G&A expenses were 10% higher YoY and approx. 1/3 of the increase was related to the entities acquired in 2024 S&M R&D G&A 8
Page 9
All data in HUFbn * Clean EBIT includes Inventory and receivables impairment and write-off/back from Jan 2025. The Q2/H1 2024 data has been restated accordingly. Strong Q2 boosts Clean EBIT (ex-FX) growth to 10% in H1 2025 10.7 -2.1 0.2 56.0 Q3 2024 71.4 3.7 -0.1-4.7 Q4 2024 48.5 12.0 14.0 -5.6 -0.2 10.1 Q1 2025 58.5 9.9 13.8 -2.9 -0.6 17.2 -5.5 Q2 2024 44.8 15.5 Q2 2025 80.4 70.6 68.7 78.7 65.1 +20.8% WHC GM CNS Pharma other BIO Pharmaceutical Clean EBIT (HUF bn)* Pharmaceutical Clean EBIT*, cumulative (HUF bn, EUR mn) -11.0 H1 2024 -8.5 H1 2025 H1 2025 FX-adjusted 128.6 147.4 87.4 33.7 20.8 -2.3 107.0 27.8 21.9 -0.8 141.4 +14.5% +9.9% Pharma other GM BIO WHC CNS Key messages • Clean EBIT (pharma) rose by 21% YoY in Q2 2025 to HUF 79bn, bringing H1 2025 Clean EBIT to HUF 147bn, up by 14.5% YoY driven by higher CNS earnings and somewhat lower BIO losses • HUF 4.5bn milestone income was booked in H1 2025, practically all in Q2 and nearly all in CNS (vs. HUF 2.7bn in H1 2024) • FX remained a tailwind in H1 2025; FX-adjusted (CER) Clean EBIT growth was 10% YoY in H1 (to HUF 141bn) • CNS was the main growth driver of and by far the largest contributor to Clean EBIT in Q2 2025 (and in H1) on the back of continued strong double-digit Vraylar sales growth and supported by some milestone income • WHC Clean EBIT was stable QoQ at HUF 14bn in Q2 2025 but declined YoY (both in Q2 and in H1) despite the very strong topline. This was mostly due to materially higher R&D expenses (new original research hub in Belgium). • GenMed’s Clean EBIT was broadly unchanged YoY, as the weaker revenue growth and elevated impairments were offset by well-controlled opex • BIO Clean EBIT losses narrowed visibly in Q2 2025 to HUF 2.9bn, supported by the teriparatide asset buyout (royalty) and lower R&D expenses 357 H1 2025 (EURmn) CER 9
Page 10
All data in HUFbn; * Profit for the period attributable to owners of the parent Below-the-line: FX turns into losses in 2025, affecting net income Other rev/exp, one-offs EBIT FX gain/losses 2.5 Net interest Other Fin inc/exp 1.5 Associates Taxes Net Profit*Minority int. 148.2 140.4 120.0 7.8 5.8 6.5 24.9 0.1 Clean EBIT Net Profit in H1 2025, below-Clean EBIT items (HUF bn) Includes taxes calculated in line with Global Minimum Tax and some deferred tax expenses Key messages • Net financials added only HUF 3.2bn to pre-tax profit in H1 (vs. HUF 24.2bn a year ago), as large FX gains booked in Q1 were more than offset by FX losses (HUF 15.9bn) recorded in Q2 on the back of the weak USD. Net interest income was HUF 2.5bn in H1, while other financials items added HUF 6.5bn (mostly derivatives) • Taxes are accounted for in accordance with the Global Minimum Tax (15%); some deferred tax expenses led to slightly higher effective tax rate in H1 2025 • Net profit was HUF 120bn in H1 2025, 13% lower YoY, as the stronger operating profit was more than offset by the lack of large FX gains that boosted H1 2024 results and a higher effective tax rate 10 Including: - HUF 9.9bn FX gain in Q1, and - HUF 15.9bn FX losses in Q2 Includes some provisions (legal) and several smaller items
Page 11
All data in HUFbn; * Acquiring intangibles predominantly includes the purchase of rights or licenses of products or product portfolios Robust free cash flow in H1, mostly paid out as dividends Op. CF W/o NWC NWC Operative CF 7.9 Interest received Capex (PP&E) FCF 5.2 Acquiring intangibles* Other M&A Dividend (prev. year) 0.0 Share buyback 154.0 38.1 115.8 12.9 110.8 11.2 93.0 Free Cash Flow in H1 2025 (HUF bn) 330 323 313 312 327 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Cash Conversion Cycle | days Key messages • Free Cash Flow was HUF 111bn in H1 2025, similar to the year ago level, as FX losses (vs FX gains a year ago) offset a stronger underlying profitability • Net Working Capital increased by HUF 38bn in H1 (of which HUF 20bn in Q2), a similar increase compared to the same period last year, thus leaving cash conversion days only slightly below the year-ago level. Ensuring safe and uninterrupted supply to patients continued to result in maintaining relatively high level of net working capital. • Most of the free cash flow was used up to cover the payments of the 2024 dividends (HUF 93bn), which increased by 18% YoY; small amount was spent on M&A • As a result, the net cash position hardly changed vs the end of 2024 Application of Cash FlowA similar increase in NWC to last year’s as supply chain challenges persist 11 35% lower YoY
Page 12
Research and Development R&D 1212
Page 13
* Ready-to-Sell Licensed pipeline13 R&D pipeline – changes during Q2 2025 Neuropsychiatry Women’s Healthcare General Medicines Biotechnology new discontinued License Own Clinical phasePreclinical phase Regulatory & Launch Phase 1 Technology Development Phase 2 Phase 3 Clinical phase RSL* Market Own
Page 14
• Denosumab biosimilar (RGB-14) marketing authorization granted by the EMA; the application is under review in the US • Tocilizumab biosimilar program (RGB-19) marketing authorization submitted to both the EMA & PMDA • Ustekinumab (RGB-26, licensed from Bio-Thera) received positive CHMP opinion • Further early phase biosimilar developments and review of in-licensing opportunities are ongoing to broaden commercial product portfolio beyond 2030 • Currently there are 2 projects in mid- to late-preclinical phase and some compounds are planned to be forwarded to IND enabling studies. CSF-1R compound is targeting two indications, women oncology indications and causal endometriosis treatment. • The European Medicines Agency (EMA) is in the process of reviewing Richter’s marketing authorization application (MAA) for the Donesta project (estetrol containing mono product for Menopause symptoms management) • AbbVie-partnered program, RGH-932 (D2/D3 agonist) entered into Phase 2 development in Generalized Anxiety Disorder, with that there are now two ongoing Phase 2 clinical trials related to the molecule • Launched two products in the cardio-metabolic portfolio • Successful bioequivalence study results in Russia related to a cardio-metabolic molecule and an OTC product • In 2025 to date all bioequivalence studies finished with positive outcome Major developments in R&D in Q2 2025 CNS GM BIO WHC Women’s Healthcare Neuropsychiatry Biotechnology General Medicines 14 R&D
Page 15
Neuropsychiatry CNS 1515
Page 16
16 CNS revenues and clean EBIT sustain double-digit growth Revenue (HUFbn) Clean EBIT (HUFbn)*Key messages Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 56.5 65.0 68.3 59.8 64.6 +14.5% Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 44.8 56.0 71.4 48.5 58.5 +30.6%• CNS revenues increased by 14.5% in Q2 2025 YoY and 14% in H1 2025 compared to H1 2024 • Clean EBIT was up by 22% in H1 and by 31% in Q2 YoY implying a strong Clean EBIT Margin of 86% in H1 2025 • Clean EBIT was supported by relatively modest increase in R&D expenses as well as development-related milestone income received from AbbVie in Q2 for the initiation of the second indication’s Phase 2 clinical trial of the RGH-932 co-development project CNS | HUF mn Q2 2024 Revenues Gross Profit Sales & Marketing G&A R&D Clawback Inventory and receivable impairment Q2 2025 Ch. % YoY 56,450 56,044 -1,077 -255 -8,302 -283 -1,342 Gross Margin % Clean EBIT 64,609 64,253 -1,507 -270 -7,898 -402 -153 Cost of Sales -406 Milestone income 0 4,468 -356 14 -12 15 99.3 40 6 -5 42 44,785 CNS 99.4 58,491 31 cEBIT Margin % 79.3 90.5 -89 All data in HUFbn * Clean EBIT includes Inventory and receivables impairment and write-off/back from Jan 2025. The Q2/H1 2024 data has been restated accordingly. H1 2024 H1 2025 Ch. % YoY 109,418 124,394 14 -782 -788 1 108,636 123,606 14 99.3 -2,087 -2,419 16 -500 -526 5 -16,593 -17,270 4 -639 -634 -1 50 4,505 n.a. -1,483 -249 n.a. 87,384 107,013 22 79.9 99.4 86.0 H1 2024 H1 2025 109.4 124.4 +13.7% H1 2024 H1 2025 87.4 107.0 +22.5%
Page 17
Vraylar® Reagila® • Royalty income from Vraylar® in Q2 2025 exceeded HUF 60bn, up nearly 15% YoY • In H1 comparison, royalty revenues increased by 14%, approaching HUF 120bn in 2025 • Global Vraylar net revenues by AbbVie were USD 900mn, an increase of 16.3% driven by strong double-digit demand growth* • On the back of the strong H1 performance, AbbVie increased its 2025 sales guidance for Vraylar (a total of USD 200mn increase in Neuroscience split relatively evenly across 3 products, including Vraylar)* • Richter’s Reagila® revenues (from own and partnered territories) grew by 7% in Q2 2025 compared to Q2 2024, and by 4% in H1 YoY • Although GR Territory (where cariprazine is distributed by Richter’s own S&M network) kept on performing double-digit growth, revenue coming from certain partnered territories decreased due to overstock or timing of deliveries Key messages Key messages Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 52.8 61.7 65.1 56.2 60.7 +14.9% H1 2023 H1 2024 H1 2025 84.1 102.3 117.0 +14.4% Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 3.6 3.4 3.2 3.5 3.9 +7.2% H1 2023 H1 2024 H1 2025 5.3 7.2 7.4 +3.6% All data in HUFbn * Source: AbbVie Q2 2025 conference call and presentation (31 July 2025) 17 Vraylar: continued strong demand growth; Reagila: picking up in Q2 CNS
Page 18
Women’s Healthcare WHC 1818
Page 19
Revenue (HUFbn) Clean EBIT (HUFbn)* Key messages Accelerating topline growth and higher R&D expenses WHC | HUF mn Q2 2024 Revenues Gross Profit Sales & Marketing G&A R&D Clawback Inventory and receivable impairment Q2 2025 Ch. % YoY 75,331 53,064 -24,257 -6,281 -3,311 -1,035 -934 Gross Margin % Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 75.3 67.6 69.1 78.8 89.9 +19.4% • WHC revenues increased by 12.9% YoY in H1 2025, as growth accelerated significantly in Q2 (+19%) • Growth was driven by the outstanding contribution of focus brands: Drovelis®, Ryeqo®, Lenzetto® and a solid performance of the Fertility portfolio. Eastern Europe and Western Europe were the best performing regions to date. • Gross margin was broadly stable YoY, however, Clean EBIT declined both in Q2 and in H1 YoY, primarily due to higher Sales and Marketing expenses (in line with plans to support the intensified promotion of the Ryeqo endometriosis launch and the geographical expansion of key brands) and much higher R&D. Latter reflects a very low base and the innovation ambitions at the newly established WHC R&D hub in Liège. 89,917 61,941 -27,390 -7,360 -9,042 -2,203 -2,146 Cost of Sales -22,267 Milestone income 0 -27,976 19 26 17 70.4 13 17 173 113 Clean EBIT 17,246 19 WHC 68.9 cEBIT Margin % 22.9 0 n.a. 130 13,800 -20 15.3 All data in HUFbn * Clean EBIT includes Inventory and receivables impairment and write-off/back from Jan 2025. The Q2/H1 2024 data has been restated accordingly. H1 2024 H1 2025 149.5 168.8 +12.9% H1 2024 H1 2025 Ch. % YoY 149,519 168,761 13 -45,520 -52,894 16 103,999 115,867 11 69.6 -46,914 -53,894 15 -12,503 -14,202 14 -6,449 -13,886 115 -3,265 -3,824 17 118 0 n.a. -1,263 -2,302 n.a. 33,723 27,759 -18 22.6 68.7 16.4 H1 2024 H1 2025 33.7 27.8 -17.7% Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 17.2 10.7 -0.1 14.0 13.8 -20.0%
Page 20
4.4 Q2 2024 7.5 41.9 6.2 7.0 4.9 Q3 2024 9.1 40.0 6.7 8.2 5.0 Q4 2024 10.8 47.6 9.0 9.0 5.3 Q1 2025 12.1 54.0 6.6 10.7 6.5 Q2 2025 50.4 5.3 6.3 75.3 67.6 69.1 78.8 89.9 6.1 +19.4% Other WHC Menopause UF and EM Fertility Contraception Total WHC revenues by therapeutic areas (quarterly, HUF bn) The positive trend of very fast growth of the smaller focus TAs (Fertility, UF/EM, and Menopause) – in line with our strategic plans – was uninterrupted in H1. Hence the share of contraception declined further to 60% from 65% a year ago. Contraception Sales growth is primarily driven by Drovelis, the newest combined oral contraceptive. The impact of last year’s emergency contraception stock movements in China and the US has slowly been smoothening out. Strong portfolio growth in Eastern Europe. Fertility Bemfola sales are back on track after supply issues in select markets. Cyclogest leads portfolio growth with 17% YoY increase. Uterine Fibroids & Endometriosis Endometriosis remains a key topic in public and social media across several EU countries. Ryeqo continues to show strong growth in all markets, supported by increased uptake of other first-line treatment options. Menopause The portfolio is driven by strong patient demand in Europe and Latin America. Lenzetto remains the lead product, with sustained growth (+59% YoY). There is a positive menopause trend on US market as well. Key messages WHC revenues by therapeutic areas (HUF bn; % in H1 2025) Contraception Fertility UF and EM Menopause 7.0% Other WHC 60.2% 13.5% 11.7% 7.6% All data in HUFbn TA split: continued diversification towards steadily growing areas 20 WHC
Page 21
Drovelis®Ryeqo® • Ryeqo®: strong growth in both Uterine Fibroids (UF) and Endometriosis indications across all EU markets • Symptomatic treatment of Endometriosis and its reimbursement was granted in Italy and Australia in H1 2025 unlocking great potential for further product growth. • Fast uptake is visible in all major EU markets • Drovelis®: solid growth YoY and further sequential increase in Q2 was driven by the combination of partners’ business and core EU markets • Strong performance across all markets. Double-digit growth in TOP-5 Western European markets and considerable uptake in mid-size LatAm markets (e.g. Chile and Ecuador) Highlighted brands Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 3.9 4.4 5.5 6.5 7.4 +90.3% H1 2023 H1 2024 H1 2025 2.4 7.1 13.9 +96.3% Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 4.1 4.6 6.5 6.2 6.6 +61.7% H1 2023 H1 2024 H1 2025 5.2 7.8 12.9 +65.6% All data in HUFbn | Ryeqo and Drovelis keep very strong momentum 21 WHC
Page 22
Bemfola®EVRA® All data in HUFbn Highlighted brands • Bemfola® sales are in line with the planned recovery from the 2024 supply chain challenges • The Fertility franchise has been growing steadily, also supported by the continued fast market penetration (and double-digit growth) of Cyclogest® • Evra® is partly driven by seasonality and the tender procurement patterns in LatAm (delay of tenders in Mexico) • Both partner business and Europe show healthy growth with strong uptake in Eastern Europe, except for Poland that was impacted negatively by stock movements Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 4.1 4.1 4.3 5.3 4.9 +18.1% H1 2023 H1 2024 H1 2025 12.4 9.4 10.1 +7.1% Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 9.9 7.9 7.7 8.2 9.6 -3.7% H1 2023 H1 2024 H1 2025 14.7 17.6 17.8 +0.9% | Lenzetto excels; Bemfola recovering; EVRA flat 22 All data in HUFbn WHC Lenzetto® Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 2.8 3.3 3.5 3.7 4.4 +56.5% H1 2023 H1 2024 H1 2025 3.3 5.1 8.1 +58.9% • Lenzetto® continues to exceed all expectations in H1 • Robust growth in UK and Nordics, followed by strong performance in LatAm (Colombia, Mexico and Chile) • New launch in Brazil and Russia
Page 23
Biotechnology BIO 2323
Page 24
Steady revenue and Clean EBIT improvement YoY Revenue (HUFbn) Clean EBIT (HUFbn)* Key messages Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 15.1 14.2 13.3 13.1 16.4 +8.6% Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 -5.5 -2.1 -4.7 -5.6 -2.9 • BIO revenues grew by close to 10 % in Q2 and H1 2025 YoY with both increased teriparatide and CDMO revenue growth contributing • Gross margins are close to flat, affected by higher cost of sales, and lower than planned volumes. Clean EBIT losses were reduced, primarily driven by lower R&D spending. • Richter’s denosumab biosimilar (RGB-14) received EC marketing authorization for Junod® and Yaxwer®, for all indications of the reference medicines Prolia® and Xgeva® of Amgen • The marketing authorization application for the tocilizumab biosimilar program (RGB-19) is under review after successful submission to EMA and PMDA in Q1 2025 • Ustekinumab (RGB-26, licensed from Bio-Thera) received positive CHMP opinion and now referred to the European Commission BIO | HUF mn Q2 2024 Revenues Gross Profit Sales & Marketing G&A R&D Clawback Inventory and receivable impairment Q2 2025 Ch. % YoY 15,080 4,791 -1,865 -1,199 -8,030 -278 -346 Gross Margin % Clean EBIT 16,383 5,716 -1,497 -1,184 -5,533 -147 -296 Cost of Sales -10,289 Milestone income 1,443 0 -10,667 9 4 19 31.8 -20 -1 -31 -47 -5,484 24 BIO 34.9 -2,941 n.a. -46 cEBIT Margin % -36.4 -18.0 n.a. All data in HUFbn * Clean EBIT includes Inventory and receivables impairment and write-off/back from Jan 2025. The Q2/H1 2024 data has been restated accordingly. H1 2024 H1 2025 Ch. % YoY 26,521 29,443 11 -16,799 -19,024 13 9,722 10,419 7 36.7 35.4 -3,618 -3,620 0 -2,111 -2,215 5 -16,696 -12,037 -28 -387 -219 -43 2,511 -10 -100 -447 -853 -11,026 -8,535 -23 -41.6 -29.0 H1 2024 H1 2025 26.5 29.4 +11.0% H1 2024 H1 2025 -11.0 -8.5 91
Page 25
• Teriparatide biosimilar (incl. Terrosa®) revenues are up YoY by 12% in H1 2025, also reflecting the positive impact of the royalty contribution from the teriparatide asset buyout. Further revenue growth has been limited by constraints on shipments, these are now being addressed. • CDMO revenues continued to grow sequentially and are also up 10% in H1 2025 YoY, but are somewhat down YoY based on quarterly figures from a high base. New CDMO orders are reflecting uncertainty in the market particularly around innovation spend and open tariff questions in relation to the US market. • The new biopharmaceutical plant at Richter Biologics in Germany is fully operational, batch manufacturing began in H1 2025 Teriparatide Key messages Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 7.0 7.3 7.1 6.1 8.5 +21.5% H1 2023 H1 2024 H1 2025 10.3 13.0 14.6 +12.0% CDMO activities Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 8.1 6.9 6.1 6.9 7.9 -2.4% H1 2023 H1 2024 H1 2025 11.0 13.5 14.8 +10.1% All data in HUFbn Both teriparatide and CDMO revenues grew by around 10% in H1 25 BIO
Page 26
General Medicines GM 2626
Page 27
Slowing dynamics in Q2 Revenue (HUFbn) Clean EBIT (HUFbn)* Key messages Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 62.9 64.8 64.5 65.5 65.3 +3.7% Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 10.1 15.5 3.7 12.0 9.9 -1.6% • Revenues grew by 8% to HUF 131bn in H1 2025, as weaker Q2 growth dynamics (+4%) offset the stronger Q1 performance • FX remained a tailwind (stronger RUB) and the price impact was also positive, but volumes were weaker in Q2 YoY, affected by a stronger base (launch-related shipments) and some supply chain issues • The core Hungarian and Russian markets continued to perform well, but some other markets underperformed (e.g. Ukraine) • Despite weaker topline growth and elevated inventory impairments (on some supply chain and quality issues), Clean EBIT rose 5% in H1 2025 YoY, helped by stronger cost control GM | HUF mn Q2 2024 Revenues Gross Profit Sales & Marketing G&A R&D Clawback Inventory and receivable impairment Q2 2025 Ch. % YoY 62,947 34,841 -13,303 -5,253 -2,994 -506 -2,699 Gross Margin % Clean EBIT 65,289 35,317 -13,296 -5,337 -2,629 -215 -3,913 Cost of Sales -28,106 -29,972 4 7 1 55.3 0 2 -12 -58 10,086 27 GM 54.1 cEBIT Margin % 16.0 45 9,927 -2 15.2 All data in HUFbn * Clean EBIT includes Inventory and receivables impairment and write-off/back from Jan 2025. The Q2/H1 2024 data has been restated accordingly. H1 2024 H1 2025 Ch. % YoY 121,420 130,830 8 -54,517 -59,321 9 66,903 71,509 7 55.1 54.7 -25,912 -27,718 7 -10,157 -11,056 9 -5,629 -5,667 1 -1,412 -891 -37 -2,969 -4,280 20,824 21,897 5 17.2 16.7 H1 2024 H1 2025 121.4 130.8 +7.7% H1 2024 H1 2025 20.8 21.9 +5.2% 44
Page 28
6.7 Q2 2024 4.4 18.6 22.7 11.8 7.3 Q3 2024 5.8 18.3 21.5 12.2 6.7 Q4 2024 4.6 19.4 4.5 13.1 7.2 Q1 2025 4.9 20.9 22.3 11.0 6.3 Q2 2025 19.0 22.8 9.8 62.9 64.8 64.5 65.5 65.3 21.3 +3.7% Blood&metabolic non-strategic TA OTC Cardiology Pain&neurology Total GenMed revenues by therapeutic areas (quarterly, HUF bn) • Blood&metabolic category shows strong YoY growth on the back of solid performance in the biggest markets: Rivaroxaban reaching #3 generic position in Russia in Q2; Richter’s Dabigatran (Telexer) is the #1 generic in HU, #2 in PL. Launch of Ticaglerol completed on Day1 of LOE in CEE, RU with good sell-out trajectory in first weeks. • Dominance in cardio combinations. HU: strong positions in cardio category, with recently launched amlo-peri-inda triple combination. KZ: Ekvamer triple combination takes leading generic position within INN • OTC strong performance by seasonal brands, also helped by low base due to different phasing of deliveries in 2024 • Pain&neurology category saw a slight decline in Q2 due to divestment of Lunaldin and some downside on Mydocalm due to out-of-stock situations New product launches in Q2 2025 • RU, PL, CEE: Ticaglerol (Blood&metabolic) • HU: Dimethyl Fumarate (Pain&neurology – multiple sclerosis) • HU, RO, SK: Fingolimod (Pain&neurology – multiple sclerosis) Key messages GenMed revenues by therapeutic areas, annual (HUF bn; % in H1 2025) Pain&neurology Cardiology OTC non-strategic TA Blood&metabolic 33.3% 30.8% 18.4% 10.3% 7.3% All data in HUFbn Mixed performance in Q2 across the key TAs 28 GM
Page 29
Appendix 2929
Page 30
Key messages • Net financials were only marginally positive in H1 2025 (HUF 3.2bn), as opposed to large financial gains recorded a year ago on the back of FX gains • Exchange rates continue to bring massive volatility to the below-the-line financial items, mostly through unrealized (and realized) gains/losses recorded on working capital items. In H1 2025 FX losses amounted to HUF 5.8bn, mostly due to the weaker USD in Q2 vs. sizeable FX gains a year ago (HUF 21.4bn) that boosted the P&L in H1 2024 • Net interest income amounted to HUF 2.5bn in H1 2025, unchanged YoY • Richter continues to use hedging transactions to mitigate some of the risks resulting from the volatility of the functional currency (or commodities), and these transactions had some positive impact (net gain) on net financials in H1 2025 7.1 -0.9 0.4 0.8 1.2 8.6 Q2 2024 -14.6 Unrealised exchange (loss)/gain -7.4 Realised exchange (loss)/gain 0.8 Result of realised & unrealised forward exchange contracts 0.0 Interest income / (Interest expense) 2.3 Other financial items -18.8 Profit (loss) from financial operations Diff Q2 All data in HUFbn FX gains turn into losses in Q2 on the weaker USD 30 -7.5 -8.2 1.2 0.8 3.5 -10.2 Q2 2025 20.2 1.2 -0.3 2.5 0.7 24.2 H1 2024 6.6 -12.4 2.3 2.5 4.2 3.2 H1 2025 -13.6 -13.6 2.7 -0.1 3.5 -21.1 Diff H1
Page 31
H1 2025 WHC CNS BIO GM Pharma other Pharma total Other Eliminations Group total Revenues 168.8 124.4 29.4 130.8 4.1 457.6 13.0 -5.0 465.5 Cost of Sales -52.9 -0.8 -19.0 -59.3 -4.3 -136.3 -10.3 5.4 -141.2 Gross Profit 115.9 123.6 10.4 71.5 -0.1 321.3 2.6 0.4 324.3 Sales & Marketing -53.9 -2.4 -3.6 -27.7 -0.1 -87.8 -1.1 0.0 -88.9 General & Administrative -14.2 -0.5 -2.2 -11.1 -0.3 -28.3 -1.0 0.0 -29.4 Research & Development -13.9 -17.3 -12.0 -5.7 -48.9 0.0 0.0 -48.9 Clawback -3.8 -0.6 -0.2 -0.9 -5.6 0.0 0.0 -5.6 Milestone income 4.5 0.0 4.5 0.0 0.0 4.5 Inventory and receivable impairment -2.3 -0.2 -0.9 -4.3 -0.2 -7.9 -0.1 0.0 -8.0 WHC: Women’s Healthcare, CNS: Neuropsychiatry, BIO: Biotechnology, GM: General Medicines All data in HUFbn Business units’ P&L in H1 2025 Note: The items of the Pharmaceutical segment's profit and loss statement are allocated to the business units by product groups, where direct correspondence exists. For the remaining items, Richter Group uses allocation keys based on historical data and management accounting estimation. 31 Clean EBIT 27.8 107.0 -8.5 21.9 -0.8 147.4 0.4 0.4 148.2 0.0 0.0 0.0 0.0 0.0
Page 32
Pharma | Pharmaceuticals segment Name of the Business Units Brief description Key strategic goal Therapeutic areas CNS Neuropsychiatry Leveraging our world class early phase R&D capability in the central nervous system domain we build a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry Maximize the potential of cariprazine, while developing and partnering original R&D projects that provide the basis for revenue and earnings growth beyond 2030 Neuropsychiatry1 WHC Women’s Healthcare We look after women’s health globally by setting trends in female contraception, fertility, menopause, uterine fibroids/endometriosis, urinary tracts, PCOS and in women’s oncology As thought leaders in women's healthcare, Richter is committed to address unmet medical needs by developing and delivering market-leading solutions in its established therapeutic segments, while also introducing novel therapies in urinary tracts, PCOS and women's oncology Women’s Healthcare BIO Biotechnology Leverage our biotechnology platform to develop and manufacture biosimilar drugs for global markets By scaling up we aim to become a relevant biosimilar player in the Immunology and Musculoskeletal TA, while we leverage our biotechnology expertise in providing value to third-party clients through our contract development and manufacturing services Immunology, Musculoskeletal GM General Medicines Comprises our established and generic portfolio in various therapeutic areas in the Central and Eastern European regions Provide broad access to high quality and affordable medications while remaining a reliable source of revenue growth, scale and margins Cardiology, Blood&Metabolic, Pain&Neurology2 Other | Other segment Non-pharmaceutical activities 1Cariprazine and innovative neuropsychiatry pipeline, 2Off-patent original CNS products and generics Strategic positioning and vision of the business units 32
Page 33
Consolidated Income Statement 33 2024 Consolidated P&L H1 2025 H1 2024 Change HUFm HUFm HUFm % 857 545 Revenues 465 509 419 693 10.9% 236 591 of which royalty 122 122 104 799 16.5% (266 807) Cost of Sales (141 191) (127 722) 10.5% 590 738 Gross Profit 324 318 291 971 11.1% (163 808) Sales & marketing expenses (88 853) (80 801) 10.0% (57 183) General & administrative expenses (29 369) (26 818) 9.5% (99 250) Research & development expenses (48 860) (45 367) 7.7% (9 069) Other income & expense (15 298) (13 124) 16.6% (11 887) of which clawback (5 568) (5 703) -2.4% 21 556 of which milestone income 4 495 2 679 67.8% (271) (Impairment)/Reversal of impairment on financial and contract assets (1 554) 624 n.a. 261 157 EBIT (Profit from operations) 140 384 126 485 11.0% 78 397 Finance income 49 515 52 515 -5.7% (65 495) Finance costs (46 339) (28 273) 63.9% 12 902 Net financial (loss)/income 3 176 24 242 -86.9% 7 018 Share of profit/(loss) of associates and joint ventures 1 495 5 902 -74.7% 281 077 Profit before income tax 145 055 156 629 -7.4% (35 513) Income and deferred tax (21 001) (13 808) 52.1% (6 040) Local business tax and innovation contribution (3 943) (4 014) -1.8% 239 524 Profit for the period 120 111 138 807 -13.5% Profit attributable to: 239 244 Owners of the parent 119 978 138 215 -13.2% 280 Non-controlling interest 133 592 -77.5% HUF Earning per share (EPS) HUF HUF 1 307 Basic 656 756 -13.2% 1 307 Diluted 656 756 -13.2%
Page 34
Consolidated Balance Sheet - ASSETS 34 Consolidated Balance Sheet 30 June 2025 31 Dec 2024 Change HUFm HUFm % ASSETS 1 601 053 1 602 991 -0.1% Non-current assets 911 096 961 934 -5.3% Property, plant and equipment 378 137 378 860 -0.2% Goodwill 35 002 38 777 -9.7% Other intangible assets 295 189 306 189 -3.6% Investments in associates and joint ventures 17 845 16 378 9.0% Non-current financial assets at amortised cost 1 222 1 335 -8.5% Non-current financial assets at FVTPL 73 968 71 531 3.4% Non-current financial assets at FVOCI 46 304 79 879 -42.0% Derivative financial instruments 14 360 15 012 -4.3% Deferred tax assets 41 685 45 660 -8.7% Long term receivables 7 384 8 313 -11.2% Current assets 689 957 641 057 7.6% Inventories 223 330 215 411 3.7% Trade receivables 254 850 240 327 6.0% Contract assets 7 872 6 721 17.1% Other current assets 43 950 40 292 9.1% Current financial assets at amortised cost 2 353 994 136.7% Financial assets at FVTPL 791 - n.a. Derivative financial instruments 9 338 9 n.a. Current tax asset 741 1 676 -55.8% Cash and cash equivalents 146 732 135 627 8.2%
Page 35
Consolidated Balance Sheet - EQUITY AND LIABILITIES 35 Consolidated Balance Sheet 30 June 2025 31 Dec 2024 Change HUFm HUFm % EQUITY AND LIABILITIES 1 601 053 1 602 991 -0.1% Capital and reserves 1 302 179 1 303 862 -0.1% Share capital 18 638 18 638 0.0% Treasury shares (33 847) (33 852) 0.0% Share premium 15 214 15 214 0.0% Capital reserves 3 475 3 475 0.0% Foreign currency translation reserves 53 276 72 777 -26.8% Revaluation reserves for financial assets at FVOCI (11 313) 11 004 n.a. Cash-flow hedge reserve 6 491 (5 726) n.a. Retained earnings 1 247 228 1 218 932 2.3% Non-controlling interest 3 017 3 400 -11.3% Non-current liabilities 123 123 123 887 -0.6% Borrowings 1 173 1 253 -6.4% Deferred tax liability 15 894 13 331 19.2% Non-current financial liabilities at FVTPL 60 371 61 132 -1.2% Derivative financial instruments 11 009 13 160 -16.3% Lease liability 14 607 14 624 -0.1% Other non-current liabilities and accruals 12 374 13 162 -6.0% Provisions 7 695 7 225 6.5% Current liabilities 175 751 175 242 0.3% Borrowings 219 365 -40.0% Trade payables 49 746 72 331 -31.2% Contract liabilities 2 292 2 530 -9.4% Current tax liabilities 32 888 25 246 30.3% Current financial liabilities at FVTPL 2 799 4 425 -36.7% Derivative financial instruments - 7 499 n.a. Lease liability 5 616 5 501 2.1% Other current liabilities and accruals 74 012 53 937 37.2% Provisions 8 179 3 408 140.0%
Page 36
Consolidated Cash Flow Statement 36 31 Dec 2024 Consolidated cash flow 30 June 2025 30 June 2024 Change HUFm HUFm HUFm % Operating activities 281 077 Profit before income tax 145 055 156 629 -7.4% 49 521 Depreciation and amortisation 29 039 23 287 24.7% 4 180 Non cash items (6 458) (5 413) 19.3% (5 692) Net interest and dividend income (1 898) (2 022) -6.1% 3 239 Other impairment recognised on intangible assets and goodwill - - n.a. 4 050 Other items 830 - n.a. (10 888) Interest paid (5 397) (7 576) -28.8% (23 565) Income tax paid (7 197) (7 432) -3.2% 301 922 Net cash flow from operating activities before changes in working capital 153 974 157 473 -2.2% (22 553) Movements in working capital (38 125) (36 512) 4.4% (22 419) Increase in trade and other receivables (23 718) (11 390) 108.2% (29 490) Increase in inventories (13 162) (28 217) -53.4% 29 356 (Increase) / decrease in payables and other liabilities (1 245) 3 095 n.a. 279 369 Net cash flow from operating activities 115 849 120 961 -4.2% Cash flow from investing activities (52 927) Payments for property, plant and equipment (12 890) (19 709) -34.6% (10 791) Payments for intangible assets (5 242) (1 678) 212.4% 2 352 Proceeds from disposal of property, plant and equipment 1 146 1 210 -5.3% (36 392) Payments to acquire financial assets (11 432) (32 243) -64.5% 52 995 Proceeds on sale or redemption on maturity of financial assets 17 067 49 529 -65.5% 87 Disbursement of loans net 246 114 115.8% 17 640 Interest received 7 860 10 101 -22.2% 21 Dividend received 43 7 514.3% (24 086) Net cash outflow on purchase of group of assets - (24 090) n.a. (17 724) Net cash outflow on acquisition of subsidiaries (935) (75 047) -98.8% (68 825)Net cash flow to investing activities (4 137) (91 806) -95.5% Cash flow from financing activities (6 937) (Purchase) / disposal of treasury shares - (6 936) n.a. (79 079) Dividend paid (93 007) (78 846) 18.0% (4 655) Principal elements of lease payments (3 605) (1 958) 84.1% (57 648) Obligations assumed during acquisitions - - n.a. (225 795) Repayment of borrowings (70) (105 011) -99.9% 218 959 Proceeds from borrowings - 139 983 n.a. (155 155)Net cash flow (to) / from financing activities (96 682) (52 768) 83.2% 55 389 Net increase / (decrease) in cash and cash equivalents 15 030 (23 613) n.a. 80 493 Cash and cash equivalents at beginning of year 135 627 80 493 68.5% (255) Effect of foreign exchange rate changes on cash and cash equivalents (3 925) 40 n.a. 135 627 Cash and cash equivalents at end of period 146 732 56 920 157.8%
Page 37
Financial calendar | 6 August 2025 – Q2/H1 2025 results | 6 November 2025 – Q1-Q3 2025 results Contacts Company name: Gedeon Richter Plc. Sector: Pharmaceutical Company address: 1103 Budapest, Gyömrői út 19-21., Hungary Telephone: +36 1 431 5764 Investor relations manager Róbert Réthy, CFA +36 20 342 2555 investor.relations@gedeonrichter.com https://www.gedeonrichter.com/en/ https://www.linkedin.com/company/richter-gedeon-hungary/ 3737
Page 38
38 Disclaimer This presentation may contain forward-looking statements, that may include, but are not limited to, those regarding capital, inv estment, cash flows, demand, earnings, efficiency, production, profits. These forward -looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from those expressed or implied by these forward -looking statements. These risks, uncertainties and other factors include, but are not limited to developments in government regulations, foreign exchange rates, political stability, economic growth, and the completion of on -going transactions. Many of these factors are beyond the company's ability to control or predict. Given these and other uncertainties, you are ca utioned not to place undue reliance on any of the forward-looking statements contained herein or otherwise. The company cannot guarantee the performa nce and does not undertake any obligation to release publicly any revisions to these forward -looking statements to reflect events or cir cumstances after the date hereof or to reflect the occurrence of unanticipated events, except as maybe required under applicable laws. Statements and data contained in this presentation and the associated slides and discussions, which relate to the performance of Richter in this and future years, represent plans, targets, or projections. The presentation does not constitute an offer to sell or issue, o r solicitation of an offer to purchase or subscribe for securities, or a recommendation. Any data in this presentation are based on publicly available i nformation of the company and can be accessed by anyone on the company’s website. Investors (gedeonrichter.com) 38